Catherine Cusack net worth and biography

Catherine Cusack Biography and Net Worth

Director of Sabra Health Care REIT

Katie Cusack has served on Sabra’s Board of Directors since January 2021. Ms. Cusack currently serves as Chief Operating Officer of Cornell Capital LLC, a $4 billion private investment firm with offices in New York and Hong Kong. From 2007 to 2020, Ms. Cusack served in various capacities at Credit Suisse, including Chief Operating Officer for the Investment Banking Division in both Asia Pacific and Europe, Middle East and Africa, and as Head of Ultra-High Net Worth Coverage. Prior to joining Credit Suisse, Ms. Cusack served as a Managing Director at MTS Health Partners LP, where she provided strategic advisory services to corporate clients in the healthcare services industry. She began her banking career at Goldman Sachs in the mergers and acquisitions group and principal investing area. Ms. Cusack serves in a volunteer capacity as a Trustee of Hudson Guild, a Chelsea-based settlement house providing social services to more than 14,000 New Yorkers.

What is Catherine Cusack's net worth?: The estimated net worth of Catherine Cusack is at least $1.04 million as of February 21st, 2025. Ms. Cusack owns 59,083 shares of Sabra Health Care REIT stock worth more than $1,036,316 as of March 28th. This net worth evaluation does not reflect any other investments that Ms. Cusack may own. Learn More about Catherine Cusack's net worth.
How do I contact Catherine Cusack?: The corporate mailing address for Ms. Cusack and other Sabra Health Care REIT executives is 18500 VON KARMAN AVENUE SUITE 550, IRVINE CA, 92612. Sabra Health Care REIT can also be reached via phone at (888) 393-8248 and via email at investorrelations@sabrahealth.com. Learn More on Catherine Cusack's contact information.
Has Catherine Cusack been buying or selling shares of Sabra Health Care REIT?: During the past quarter, Catherine Cusack has bought $40,310.00 in Sabra Health Care REIT stock. Most recently, on Monday, February 24th, Catherine Cusack bought 1,500 shares of Sabra Health Care REIT stock. The stock was acquired at an average cost of $15.92 per share, with a total value of $23,880.00. Following the completion of the transaction, the director now directly owns 60,583 shares of the company's stock, valued at $964,481.36. Learn More on Catherine Cusack's trading history.
Who are Sabra Health Care REIT's active insiders?: Sabra Health Care REIT's insider roster includes Harold Andrews, Jr. (CFO), Michael Costa (CFO), Catherine Cusack (Director), and Michael Foster (Director). Learn More on Sabra Health Care REIT's active insiders.
Are insiders buying or selling shares of Sabra Health Care REIT?: During the last twelve months, Sabra Health Care REIT insiders bought shares 3 times. They purchased a total of 9,500 shares worth more than $141,320.00. The most recent insider tranaction occured on February, 24th when Director Catherine Cusack bought 1,500 shares worth more than $23,880.00. Insiders at Sabra Health Care REIT own 1.1% of the company. Learn More about insider trades at Sabra Health Care REIT.
Information on this page was last updated on 2/24/2025.

Catherine Cusack Insider Trading History at Sabra Health Care REIT

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/24/2025	Buy	1,500	$15.92	$23,880.00	60,583
2/21/2025	Buy	1,000	$16.43	$16,430.00	59,083
5/22/2024	Buy	7,000	$14.43	$101,010.00	46,385
5/13/2021	Buy	2,000	$17.19	$34,380.00
3/2/2021	Buy	1,000	$17.34	$17,340.00	2,891

Catherine Cusack Buying and Selling Activity at Sabra Health Care REIT

Sabra Health Care REIT Company Overview

Sabra Health Care REIT, Inc. engages in the business of acquiring, financing, and owning real estate property. The company was founded on May 10, 2010 and is headquartered in Tustin, CA.

Today's Range

Now: $17.54

$17.30

$17.58

50 Day Range

MA: $16.82

$15.88

$17.78

2 Week Range

Now: $17.54

$13.31

$20.03

Volume

1,748,458 shs

Average Volume

2,083,186 shs

Market Capitalization

$4.17 billion

P/E Ratio

33.09

Dividend Yield

6.92%

Beta

1.27